simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine
Phase 2TerminatedDevelopment Stage
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Feb 19, 2018 → Dec 30, 2021
About simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine
simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine is a phase 2 stage product being developed by Roche for Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers. The current trial status is terminated. This product is registered under clinical trial identifier NCT03386721. Target conditions include Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03386721 | Phase 2 | Terminated |
Competing Products
20 competing products in Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers